217 related articles for article (PubMed ID: 20158099)
1. [Effects of PPARgamma agonist on dyslipidemia and atherosclerosis].
Komatsu A; Node K
Nihon Rinsho; 2010 Feb; 68(2):294-8. PubMed ID: 20158099
[TBL] [Abstract][Full Text] [Related]
2. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature.
Duan SZ; Usher MG; Mortensen RM
Circ Res; 2008 Feb; 102(3):283-94. PubMed ID: 18276926
[TBL] [Abstract][Full Text] [Related]
3. [Recent trends in PPARgamma agonist development of thiazolidinediones and non-thiazolidinediones].
Tanaka T
Nihon Rinsho; 2010 Feb; 68(2):249-55. PubMed ID: 20158092
[TBL] [Abstract][Full Text] [Related]
4. Thiazolidinediones and PPARγ agonists: time for a reassessment.
Cariou B; Charbonnel B; Staels B
Trends Endocrinol Metab; 2012 May; 23(5):205-15. PubMed ID: 22513163
[TBL] [Abstract][Full Text] [Related]
5. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
Tjokroprawiro A
Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
[TBL] [Abstract][Full Text] [Related]
6. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.
Fogo AB
Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479
[TBL] [Abstract][Full Text] [Related]
7. Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients.
Panunti B; Fonseca V
Vascul Pharmacol; 2006 Jul; 45(1):29-35. PubMed ID: 16777491
[TBL] [Abstract][Full Text] [Related]
8. Pioglitazone increases macrophage apoptosis and plaque necrosis in advanced atherosclerotic lesions of nondiabetic low-density lipoprotein receptor-null mice.
Thorp E; Kuriakose G; Shah YM; Gonzalez FJ; Tabas I
Circulation; 2007 Nov; 116(19):2182-90. PubMed ID: 17967777
[TBL] [Abstract][Full Text] [Related]
9. Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor gamma in vascular smooth muscle cells.
Bruemmer D; Yin F; Liu J; Berger JP; Sakai T; Blaschke F; Fleck E; Van Herle AJ; Forman BM; Law RE
Circ Res; 2003 Aug; 93(4):e38-47. PubMed ID: 12881480
[TBL] [Abstract][Full Text] [Related]
10. Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes.
Blaschke F; Caglayan E; Hsueh WA
Endocrinol Metab Clin North Am; 2006 Sep; 35(3):561-74, ix. PubMed ID: 16959586
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activated receptor-alpha,gamma-agonist improves insulin sensitivity and prevents loss of left ventricular function in obese dyslipidemic mice.
Verreth W; Ganame J; Mertens A; Bernar H; Herregods MC; Holvoet P
Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):922-8. PubMed ID: 16456093
[TBL] [Abstract][Full Text] [Related]
12. [The role of PPARgamma agonists in kidney diseases].
Yokoyama Y; Doi S; Kawai T; Yorioka N
Nihon Rinsho; 2010 Feb; 68(2):317-22. PubMed ID: 20158103
[TBL] [Abstract][Full Text] [Related]
13. Peroxisome proliferator-activated receptor gamma (PPARgamma): Is the genomic activity the only answer?
Luconi M; Cantini G; Serio M
Steroids; 2010; 75(8-9):585-94. PubMed ID: 19900469
[TBL] [Abstract][Full Text] [Related]
14. Can PPARgamma agonists have a role in the management of obesity-related hypertension?
Chetty VT; Sharma AM
Vascul Pharmacol; 2006 Jul; 45(1):46-53. PubMed ID: 16713364
[TBL] [Abstract][Full Text] [Related]
15. Diabetes and cardiovascular risk markers.
Erdmann E
Curr Med Res Opin; 2005; 21 Suppl 1():S21-8. PubMed ID: 15811196
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation.
Belvisi MG; Hele DJ; Birrell MA
Eur J Pharmacol; 2006 Mar; 533(1-3):101-9. PubMed ID: 16458290
[TBL] [Abstract][Full Text] [Related]
17. Vascular effects of PPARgamma activators - from bench to bedside.
Marx N; Walcher D
Prog Lipid Res; 2007 Nov; 46(6):283-96. PubMed ID: 17637478
[TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferator-activated receptor gamma-independent effects of thiazolidinediones on human cardiac myofibroblast function.
Mughal RS; Warburton P; O'Regan DJ; Ball SG; Turner NA; Porter KE
Clin Exp Pharmacol Physiol; 2009 May; 36(5-6):478-86. PubMed ID: 19673929
[TBL] [Abstract][Full Text] [Related]
19. Diabetes: New conductors for the peroxisome proliferator-activated receptor γ (PPARγ) orchestra.
Whitehead JP
Int J Biochem Cell Biol; 2011 Aug; 43(8):1071-4. PubMed ID: 21558015
[TBL] [Abstract][Full Text] [Related]
20. PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia.
Hennuyer N; Tailleux A; Torpier G; Mezdour H; Fruchart JC; Staels B; Fiévet C
Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1897-902. PubMed ID: 15994444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]